SEARCH
ENGLISH
According to Frost & Sullivan, the global pharmaceutical market will increase from US$1,153.0 billion in 2016 to US$1,298.8 billion in 2020, representing a CAGR of 3.0%. Among them, the global market size of peptide drugs has increased from US$56.8 billion in 2016 to US$62.8 billion in 2020, with a compound annual growth rate of 2.6%. The United States and the European Union have always occupied the market size of the global peptide drugs. The market size of peptide drugs in the United States increased from US$34 billion in 2016 to US$36.1 billion in 2020, with a compound annual growth rate of 1.4%; the market size of the EU rose from US$9.8 billion in 2016 to US$10.2 billion in 2020, The compound annual growth rate is 1%; China's peptide drug market has risen from $6.3 billion in 2016 to $8.5 billion in 2020, with a compound annual growth rate of 8%, far exceeding the global growth rate. Our company provides peptide drugs list if you are interested.
According to Frost & Sullivan's forecast, the global pharmaceutical market is expected to reach US$1,711.4 billion in 2025, with a compound annual growth rate of 5.7% from 2020 to 2025. The peptide drug market is expected to increase by US$33.2 billion to US$96 billion in 2025, with a CAGR of 8.8% from 2020 to 2025.
The U.S. peptide drug market will increase from US$36.1 billion in 2020 to US$51.2 billion in 2025, with a compound annual growth rate of 7.3%, and further increase to US$71.8 billion in 2030, with a CAGR of 7.0% from 2025 to 2030.
The European peptide drug market is expected to increase from US$10.2 billion in 2020 to US$13.8 billion in 2025, with a compound annual growth rate of 6.2%, and further increase to 18.5 billion US dollars in 2030, with a compound annual growth rate of 6.1% from 2025 to 2030.
China's peptide drug market is expected to increase from US$8.5 billion in 2020 to US$18.2 billion in 2025, with a compound annual growth rate of 16.3%, and further increase to US$32.8 billion in 2030, with a compound annual growth rate from 2025 to 2030 The rate is 12.5%. As one of the leading peptide synthesis suppliers in China, we are confident about our business development in the future.
The peptide industry has a history of more than 100 years since the official application of insulin, and has created many blockbuster products. At the same time, peptide drugs are restricted by various technical barriers, and market competition is relatively relaxed. With the development of omics technology, information technology, gene technology, and disease biology, in the post-epidemic era and the world situation where new and old production capacities alternate, the new peptide economy will become one of the new drivers of the global new economy. Therefore, our company also provides peptide wholesale business services to keep pace with the times. With the continued approval of the bifunctional peptides Pegcetacoplan and Tirzepatide, the peptide new economy industry will surely become the new focus of capital, and those global peptide new economy companies that have source technology innovation platforms and solve real clinical unmet needs will stand out.
English 
